Skip to main content
. 2022 Sep 8;9(32):2204067. doi: 10.1002/advs.202204067

Figure 6.

Figure 6

PRNsMT plus NIR‐II irradiation synergizes with α‐PD1 blockade therapy and prevents tumor metastasis. A) Subcutaneous 4T1 tumor model was established 8 days before treatment. The mice were treated with different formulations, following with NIR‐II light irradiation to eliminate the primary tumors on the flanks. To facilitate the monitor of metastasis, living 4T1 cells stably expressing luciferase activity (Luc‐4T1) were i.v. injected into the Balb/c mice. B) The distribution of Luc‐4T1 cells in mice were tracked by bioluminescence images on 12, 18, and 24 days after Luc‐4T1 cell injection. C) Corresponding quantifications of tumor bioluminescence on day 24. D) Morbidity‐free survival of mice in response to different treatments (n = 8). E) Representative photographs of lung lobes as viewed by stereo microscope (the red circles indicated metastatic nodules). F) Calculation of the number of metastatic niches after different treatments (n = 8). Data are shown as mean ± SD by one‐way analysis of variance (ANOVA) or two‐way ANOVA with Tukey's multiple comparisons test (n = 5). **p < 0.005, ***p < 0.001, ****p < 0.0001.